SG10201506273PA - Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug - Google Patents

Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug

Info

Publication number
SG10201506273PA
SG10201506273PA SG10201506273PA SG10201506273PA SG10201506273PA SG 10201506273P A SG10201506273P A SG 10201506273PA SG 10201506273P A SG10201506273P A SG 10201506273PA SG 10201506273P A SG10201506273P A SG 10201506273PA SG 10201506273P A SG10201506273P A SG 10201506273PA
Authority
SG
Singapore
Prior art keywords
cyclodextrin
preserving
methods
pharmaceutical compositions
injectable pharmaceutical
Prior art date
Application number
SG10201506273PA
Other languages
English (en)
Inventor
Kirby Shawn Pasloske
Kai Lau
Sarah Jane Richardson
Amanda Aileen Willis
Original Assignee
Jurox Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011904970A external-priority patent/AU2011904970A0/en
Application filed by Jurox Pty Ltd filed Critical Jurox Pty Ltd
Publication of SG10201506273PA publication Critical patent/SG10201506273PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201506273PA 2011-11-29 2012-11-27 Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug SG10201506273PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2011904970A AU2011904970A0 (en) 2011-11-29 Pharmaceutical compositions
AU2012904962A AU2012904962A0 (en) 2012-11-09 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
SG10201506273PA true SG10201506273PA (en) 2015-09-29

Family

ID=48534526

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201401597TA SG11201401597TA (en) 2011-11-29 2012-11-27 Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug
SG10201506273PA SG10201506273PA (en) 2011-11-29 2012-11-27 Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201401597TA SG11201401597TA (en) 2011-11-29 2012-11-27 Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug

Country Status (19)

Country Link
US (4) US9492552B2 (ja)
EP (2) EP2785352B1 (ja)
JP (2) JP5819005B2 (ja)
KR (1) KR101922752B1 (ja)
CN (2) CN107261152B (ja)
AR (1) AR089004A1 (ja)
AU (1) AU2012268889B2 (ja)
BR (1) BR112014012985B1 (ja)
CA (1) CA2852716C (ja)
DK (1) DK2785352T3 (ja)
ES (1) ES2784629T3 (ja)
HK (1) HK1198325A1 (ja)
HR (1) HRP20200567T1 (ja)
IL (1) IL232860B (ja)
IN (1) IN2014KN01341A (ja)
SG (2) SG11201401597TA (ja)
TW (1) TWI552770B (ja)
WO (1) WO2013078500A1 (ja)
ZA (1) ZA201402895B (ja)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013273764B2 (en) * 2011-11-29 2016-05-05 Zoetis Services Llc Pharmaceutical compositions
SI2806877T1 (sl) 2012-01-23 2020-01-31 Sage Therapeutics, Inc. Nevroaktivne steroidne formulacije, ki obsegajo kompleks alopregnanolona in sulfobutil etra beta-ciklodekstrina
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
CN104902919B (zh) 2012-12-21 2018-11-20 赛诺菲 Glp1/gip双重激动剂或glp1/gip/胰高血糖素三重激动剂
JP6180241B2 (ja) * 2013-08-29 2017-08-16 学校法人同志社 シクロデキストリン誘導体及び医薬組成物
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
EP3294953B1 (en) 2015-04-01 2019-07-24 International Dioxcide Inc. Stabilized composition for combined odor control and enhanced dewatering
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
KR101718733B1 (ko) * 2015-08-21 2017-03-22 국제약품 주식회사 레바미피드의 가용화 방법 및 이에 의해 제조된 안구건조증 치료용 액제
NL2015865B1 (en) * 2015-11-27 2017-06-13 Le Vet B V Maropitant Formulation.
GB201609222D0 (en) 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
CN110215430A (zh) * 2018-03-02 2019-09-10 刘力 新型可注射的硝酸甘油药物组合物
KR102141826B1 (ko) * 2018-10-05 2020-08-07 건국대학교 산학협력단 양이온성 베타 시클로덱스트린 올리고머를 이용한 외부 pH 자극 반응형 자가치유성 하이드로젤
WO2020093256A1 (zh) * 2018-11-07 2020-05-14 比卡生物科技（广州）有限公司 一种澄清丙泊酚注射液及其制备方法
WO2020167476A1 (en) 2019-02-15 2020-08-20 Saol International Limited Injectable phenol formulations and methods of their use
EP3725298A1 (en) 2019-04-16 2020-10-21 Faes Farma, S.A. Stable and preserved pharmaceutical compositions of bilastine
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
CA3087667A1 (en) 2019-07-15 2021-01-15 Op-Hygiene Ip Gmbh Wipes
FR3117337B1 (fr) * 2020-12-10 2023-04-28 Centre Hospitalier Univ De Lille Composition pharmaceutique contenant du propofol, une cyclodextrine ou un dérivé de cyclodextrine et un sel pharmaceuticalement acceptable
KR20230122271A (ko) 2022-02-14 2023-08-22 주식회사 에이아이인사이트 파라벤계 보존제의 안정성 증진용 조성물 및 이를 포함하는 보존제

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4728509A (en) * 1985-08-19 1988-03-01 Takeda Chemical Industries, Ltd. Aqueous liquid preparation
TW401300B (en) * 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
JPH06293638A (ja) * 1993-04-06 1994-10-21 Lion Corp 安定なビタミンａ類点眼剤
ZA962214B (en) * 1995-04-10 1996-10-07 Farmarc Nederland Bv Pharmaceutical composition
JP3934705B2 (ja) 1995-05-26 2007-06-20 ノバルティス ファーマ株式会社 サイクロデキストリン組成物
TW434023B (en) 1995-09-18 2001-05-16 Novartis Ag Preserved ophthalmic composition
JP2002523475A (ja) 1998-09-02 2002-07-30 アラーガン・セイルズ・インコーポレイテッド 防腐したシクロデキストリン含有組成物
AUPQ633900A0 (en) 2000-03-20 2000-04-15 Jurox Pty Ltd Anaesthetic composition
IN187686B (ja) * 2000-06-21 2002-06-08 Bharat Serums & Vaccines Ltd
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
JP2003089632A (ja) * 2001-09-17 2003-03-28 Otsuka Pharmaceut Factory Inc 注射用水性製剤
US20050239746A1 (en) * 2002-02-01 2005-10-27 Penkler Lawrence J Pharmaceutical composition
US6869939B2 (en) 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
JP4275394B2 (ja) * 2002-12-05 2009-06-10 株式会社大塚製薬工場 注射用シロスタゾール水性製剤
ES2638113T3 (es) * 2004-01-30 2017-10-18 Zoetis Services Llc Conservantes antimicrobianos para lograr una formulación de dosis múltiples usando ciclodextrinas beta para formas de dosificación líquidas
US6969706B1 (en) * 2004-05-12 2005-11-29 Allergan, Inc. Preserved pharmaceutical compositions comprising cyclodextrins
EP2767163A1 (en) 2005-02-17 2014-08-20 Abbott Laboratories Transmucosal administration of drug compositions for treating and preventing disorders in animals
CN101360503A (zh) * 2005-11-18 2009-02-04 阿斯利康公司 液体制剂
CN104958296B (zh) * 2008-11-15 2017-12-01 麦林塔医疗有限公司 抗微生物组合物
KR101747476B1 (ko) * 2010-01-21 2017-06-14 드로브리지 파마슈티컬스 피티와이 엘티디 마취 제제

Also Published As

Publication number Publication date
EP2785352A1 (en) 2014-10-08
SG11201401597TA (en) 2014-05-29
TWI552770B (zh) 2016-10-11
TW201328721A (zh) 2013-07-16
JP5819005B2 (ja) 2015-11-18
US20170014428A1 (en) 2017-01-19
IL232860A0 (en) 2014-07-31
ES2784629T8 (es) 2020-11-23
US10188664B2 (en) 2019-01-29
AU2012268889B2 (en) 2013-12-19
KR20140113629A (ko) 2014-09-24
CN107261152A (zh) 2017-10-20
KR101922752B1 (ko) 2018-11-27
CN103998046B (zh) 2021-04-06
IN2014KN01341A (ja) 2015-10-16
US9492552B2 (en) 2016-11-15
EP2785352A4 (en) 2015-07-29
DK2785352T3 (da) 2020-05-25
CN103998046A (zh) 2014-08-20
JP2015145364A (ja) 2015-08-13
NZ706101A (en) 2016-03-31
BR112014012985B1 (pt) 2020-05-12
AR089004A1 (es) 2014-07-23
JP2014533703A (ja) 2014-12-15
CN107261152B (zh) 2022-03-04
US20190125762A1 (en) 2019-05-02
IL232860B (en) 2019-10-31
ZA201402895B (en) 2015-11-25
HRP20200567T1 (hr) 2020-06-26
JP6095707B2 (ja) 2017-03-15
CA2852716C (en) 2015-11-17
CA2852716A1 (en) 2013-06-06
AU2012268889A1 (en) 2013-06-13
US20230293550A1 (en) 2023-09-21
WO2013078500A1 (en) 2013-06-06
EP2785352B1 (en) 2020-03-11
EP3446692A1 (en) 2019-02-27
US20140336163A1 (en) 2014-11-13
HK1198325A1 (zh) 2015-04-02
ES2784629T3 (es) 2020-09-29
NZ624592A (en) 2015-07-31
BR112014012985A2 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
HK1198325A1 (zh) 包含環糊精和疏水性藥物的可注射藥物組合物的防腐方法
IL276012B (en) Pharmaceutical preparations containing sorbitan esters
IL236024A (en) The history of benzimidazole-proline and its pharmaceutical preparations
IL233756A (en) History of hydroxamic acid and their pharmaceutical preparations
EP2705490A4 (en) Pharmaceutical packaging and method for delivery of same
IL229267A0 (en) A pharmaceutical composition containing dapaglifosine and cyclodextrin
GB201104473D0 (en) Improved pharmaceutical compositions and methods of delivery
EP2616053A4 (en) PHARMACEUTICAL COMPOSITIONS FROM CURCUMIN
EP2599484A4 (en) INJECTABLE PHARMACEUTICAL PREPARATION OF MELPHALANE
HK1198939A1 (en) Pharmaceutical preparation comprising brexpiprazole and substituted beta - cyclodextrin brexpiprazole -
HRP20180567T1 (hr) Farmaceutski pripravak omeprazola
EP2865379A4 (en) USE OF INULA LINEARIIFOLIA LACTONE IN PREPARATION OF A MEDICAMENT FOR TREATING MULTIPLE SCLEROSIS
HRP20160928T1 (hr) Farmaceutske kompozicije koje sadrže anakinra bez citrata
HK1198910A1 (en) Pharmaceutical composition comprising ebastine and fluticasone
HRP20180781T1 (hr) Farmaceutski pripravak koji sadržava lidipidipin i proces pripreme
GB201110598D0 (en) Pharmaceutical compositions and devices